Advertisement

The role of brachytherapy in treatment of stage I esophageal cancer: A systematic review

      ABSTRACT

      PURPOSE

      Despite advancements in the early detection of esophageal cancer, optimal radiotherapy methods for treatment of early disease have not yet been determined. Moreover, the benefit of intraluminal brachytherapy on local control or survival remains controversial. We performed a systematic review to establish the role of brachytherapy as boost therapy in stage I esophageal squamous cell carcinoma, and to evaluate associated survival outcomes.

      METHODS AND MATERIALS

      A systematic search of three bibliographic databases from January 1950 to January 2019 was conducted. All studies investigating brachytherapy for curative intent were included and palliative treatment was excluded. Primary outcomes included overall survival and disease-free survival (DFS). Secondary outcomes included loco-regional control (LRC) and toxicity grades and/or complications. Two reviewers independently abstracted data and evaluated study quality using grading of recommendations assessment, development, and evaluation, pooled results were presented through risk ratios.

      RESULTS

      A total of 12 retrospective studies met inclusion criteria. The overall quality of evidence yielded a Grade 1C rating (strong recommendation, low quality evidence). Of 525 included patients, 325 patients received both external beam radiation (EBRT), and brachytherapy, 132 underwent EBRT only, and 68 received brachytherapy with and/or without chemoradiation. For patient group treated with EBRT and brachytherapy, 5-year mortality, DFS and LRC were: 43% (27–59%), 63% (49–76%) and 72% (63–80%) respectively. Rates of complications reported included 82.1% Grade 1 esophagitis for a combined external beam radiation and brachytherapy cohort, 12.3% ulcerations, and 3.3% fistulae.

      CONCLUSIONS

      Brachytherapy as a combined modality is encouraging, given its relative safety and effectiveness. Further prospective analysis using higher quality evidence is warranted to evaluate oncologic outcomes and survival advantage.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • et al.
        Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/CAAC.21660
        • Tamaki T.
        • Ishikawa H.
        • Takahashi T.
        • et al.
        Comparison of efficacy and safety of low-dose-rate vs. high-dose-rate intraluminal brachytherapy boost in patients with superficial esophageal cancer.
        Brachytherapy. 2012; 11: 130-136https://doi.org/10.1016/J.BRACHY.2011.05.008
        • Skowronek J.
        Current status of brachytherapy in cancer treatment – short overview.
        J Contemp Brachytherapy. 2017; 9: 581https://doi.org/10.5114/JCB.2017.72607
        • Lettmaier S.
        • Strnad V.
        Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique.
        J Contemp Brachytherapy. 2014; 6: 236https://doi.org/10.5114/JCB.2014.43780
        • Akagi Y.
        • Hirokawa Y.
        • Kagemoto M.
        • et al.
        Optimum fractionation for high-dose-rate endoesophageal brachytherapy following external irradiation of early stage esophageal cancer.
        Int J Radiat Oncol. 1999; 43: 525-530https://doi.org/10.1016/S0360-3016(98)00433-7
        • Shioyama Y.
        • Nakamura K.
        • Sasaki T.
        • et al.
        Clinical results of radiation therapy for stage I esophageal cancer: a single institutional experience.
        Am J Clin Oncol Cancer Clin Trials. 2005; 28: 75-80https://doi.org/10.1097/01.COC.0000139021.91718.EE
        • Yamada K.
        • Murakami M.
        • Okamoto Y.
        • et al.
        Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma.
        Int J Radiat Oncol. 2006; 64: 1106-1111https://doi.org/10.1016/J.IJROBP.2005.10.015
        • Hareyama M.
        • Nishio M.
        • Kagami Y.
        • et al.
        Intracavitary brachytherapy combined with external-beam irradiation for squamous cell carcinoma of the thoracic esophagus.
        Int J Radiat Oncol. 1992; 24: 235-240https://doi.org/10.1016/0360-3016(92)90677-A
        • Hishikawa Y.
        • Kurisu K.
        • Taniguchi M.
        • et al.
        High-dose-rate intraluminal brachytherapy for esophageal cancer: 10 years experience in Hyogo College of Medicine.
        Radiother Oncol. 1991; 21: 107-114https://doi.org/10.1016/0167-8140(91)90082-R
        • Ishikawa H.
        • Sakurai H.
        • Tamaki Y.
        • et al.
        Radiation therapy alone for stage I (UICC T1N0M0) squamous cell carcinoma of the esophagus: indications for surgery or combined chemoradiotherapy.
        J Gastroenterol Hepatol. 2006; 21: 1290-1296https://doi.org/10.1111/J.1440-1746.2006.04089.X
        • Ishikawa H.
        • Sakurai H.
        • Yamakawa M.
        • et al.
        Clinical outcomes and prognostic factors for patients with early esophageal squamous cell carcinoma treated with definitive radiation therapy alone.
        J Clin Gastroenterol. 2005; 39: 495-500https://doi.org/10.1097/01.MCG.0000165662.49036.2E
        • Kodaira T.
        • Fuwa N.
        • Tachibana H.
        • et al.
        Retrospective analysis of definitive radiotherapy for patients with superficial esophageal carcinoma: consideration of the optimal treatment method with a focus on late morbidity.
        Radiother Oncol. 2010; 95: 234-239https://doi.org/10.1016/J.RADONC.2010.01.005
        • Liu H.
        • Wang Q.
        • Jia X.
        • et al.
        Early-stage esophageal squamous cell carcinoma treated with californium-252 neutron brachytherapy.
        Clinical Report on 16 Cases. 2018; 99: 172-175https://doi.org/10.1177/030089161309900209
        • Murakami M.
        • Kuroda Y.
        • Nakajima T.
        • et al.
        Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1-T2 esophageal carcinoma.
        Int J Radiat Oncol. 1999; 45: 277-284https://doi.org/10.1016/S0360-3016(99)00171-6
        • Sai H.
        • Mitsumori M.
        • Araki N.
        • et al.
        Long-term results of definitive radiotherapy for stage I esophageal cancer.
        Int J Radiat Oncol. 2005; 62: 1339-1344https://doi.org/10.1016/J.IJROBP.2004.12.042
      1. Cancer Statistics Review, 1975-2015 - SEER Statistics. Accessed on April 23, 2022. Available at: https://seer.cancer.gov/archive/csr/1975_2015.

        • Matsumoto S.
        • Takayama T.
        • Tamamoto T.
        • et al.
        A comparison of surgery and radiation therapy for CT1 esophageal squamous cell carcinoma.
        Dis Esophagus. 2011; 24: 411-417https://doi.org/10.1111/J.1442-2050.2010.01163.X
        • Zhang H.Z.
        • Jin G.F.
        • Shen H.B.
        Epidemiologic differences in esophageal cancer between Asian and Western populations.
        Chin J Cancer. 2012; 31: 281https://doi.org/10.5732/CJC.011.10390
        • Zhao L.
        • Zhou Y.
        • Pan H.
        • et al.
        Radiotherapy alone or concurrent chemoradiation for esophageal squamous cell carcinoma in elderly patients.
        J Cancer. 2017; 8: 3242https://doi.org/10.7150/JCA.20835
        • Al-Batran S.E.
        • Homann N.
        • Pauligk C.
        • et al.
        Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomized, phase II/III trial.
        Lancet. 2019; 393: 1948-1957https://doi.org/10.1016/S0140-6736(18)32557-1